The gut microbiome acts like a metabolic organ, and centenarians share a characteristic microbial signature, though causation is unproven. The strongest human evidence is for pasteurized Akkermansia muciniphila: two randomized trials improved insulin sensitivity in metabolic patients, with benefit only in people who started with low levels. Fiber diversity remains the most reliable lever, while probiotics, postbiotics and FMT have narrower or weaker evidence.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does Akkermansia muciniphila work?
For metabolic markers, yes in two small trials. Pasteurized A. muciniphila improved insulin sensitivity about 29% and cut fasting insulin 34% in 32 insulin-resistant adults, and a 2026 trial in metabolic syndrome found the benefit only in people with low baseline levels. The live form did not work.12
Is Akkermansia a longevity supplement?
No trial supports that. The longevity link is associative, since centenarians carry more of it, and mechanistic, while all human data is on metabolic endpoints.
What are postbiotics?
Preparations of inanimate microbes or their components that confer a benefit: defined metabolites, cell-wall proteins or heat-killed bacteria. They aim for probiotic-like effects without live organisms, with better safety and shelf stability.
Does FMT work for anything besides C. diff?
FMT is FDA-approved only for recurrent C. difficile, where cure rates exceed 90%. For obesity, a meta-analysis found no metabolic improvement, and no human trial has tested it for aging.
What would change this rating?
Human trials of microbiome interventions against aging endpoints, and evidence that transferring a centenarian microbiome transfers any longevity benefit. Both are currently untested.1
02Overview
The gut microbiome — the trillions of microorganisms inhabiting the human intestine — functions as a virtual organ influencing metabolism, immunity, neurotransmission, and aging. This file covers the microbiome through the lens of healthspan optimization and longevity, with emphasis on:
- Akkermansia muciniphila — the next-generation probiotic with the strongest human clinical evidence
- Short-chain fatty acids (SCFAs) — the primary postbiotic metabolites driving gut-systemic signaling
- The centenarian microbiome signature — taxa consistently enriched in extreme longevity
- Postbiotics — the shift from live bacteria to defined microbial metabolites as therapeutics
03The Longevity Microbiome: Centenarian Signatures
Consistent Findings Across Populations
Cross-cultural studies of centenarians (Italian, Japanese, Chinese cohorts) consistently identify specific taxa enriched in extreme agers compared to elderly non-centenarians:
| Taxon | Role | Centenarian Pattern |
|---|---|---|
| Akkermansia muciniphila | Mucin degradation, gut barrier integrity, metabolic health | ↑ Enriched in centenarians across populations |
| Christensenellaceae | Most heritable gut taxon; negatively correlated with BMI; enriched in healthy aging | ↑ Strong centenarian marker |
| Ruminococcaceae (Clostridium XIVa) | SCFA production, especially butyrate | ↑ Enriched; associated with high-fiber diets |
| Bifidobacterium | Barrier integrity, immune modulation | ↓ Declines with age but retained at higher levels in centenarians |
| Bacteroidaceae | Generalist fermenters | ↓ Decreased in centenarians vs. elderly |
Swipe table →
Key Findings
- A 2025 narrative review (Tseng, PMID via PMC: PMC12515389) synthesized gut microbiome-aging data, confirming that Christensenellaceae, Akkermansia, and Ruminococcaceae are the most consistent longevity-associated taxa across Italian, Japanese, and Chinese centenarian cohorts
- Maria Branyas Morera (117 years, 168 days) — A February 2025 Barcelona preprint detailed her genetic and microbiome profile, showing enrichment in longevity-associated taxa and exceptional microbial diversity for her age
- Centenarian microbiomes show greater alpha diversity and reduced pro-inflammatory taxa (Enterobacteriaceae, Proteobacteria) compared to age-matched elderly
- The pattern suggests that centenarians don't just "avoid" microbial decline — they actively maintain a younger-associated microbiome configuration
Causation vs. Association: Centenarians likely differ from ordinary elderly in many ways (genetics, diet, lifestyle) beyond microbiome composition. Whether transferring their microbiome to others would transfer longevity is an untested hypothesis (though animal FMT studies are suggestive — see below).
04Akkermansia muciniphila: Evidence Deep Dive
A. muciniphila is a Gram-negative, mucin-degrading bacterium that resides in the mucus layer of the gut. It is the most-studied next-generation probiotic for metabolic health.
Mechanism of Action
- Mucin turnover — Degrades mucin, stimulating the goblet cells to produce more → thicker, healthier mucus barrier
- Gut barrier integrity — Strengthens tight junctions, reduces endotoxemia (LPS translocation)
- Immune modulation — Increases Treg cells, reduces systemic inflammation
- Metabolic signaling — Produces SCFAs (acetate, propionate), influences GLP-1 secretion
- Akkermansia muciniphila protein (Amuc_1100) — A specific outer membrane protein that recapitulates many benefits of the whole bacterium, identified as a key bioactive component
Pasteurized vs. Live: The Critical Distinction
The pasteurized (heat-killed) form consistently outperforms the live form in clinical trials. This is a critical and counterintuitive finding:
- Depommier et al. 2019 (Nature Medicine, PMID: 31263284): The pivotal RCT
- 32 overweight/obese insulin-resistant adults, 3-month double-blind RCT
- Pasteurized A. muciniphila (10^10 cells/day): insulin sensitivity +28.6% (p=0.002), fasting insulin −34.1% (p=0.006), total cholesterol −8.7% (p=0.02)
- Live form: No significant effect vs. placebo
- Safety: Well-tolerated; adverse events similar to placebo (some borborgymi with live bacteria)
- Mechanism hypothesis: Pasteurization makes the Amuc_1100 outer membrane protein more accessible to the host immune system
2026 RCT — Suenaert et al.
Suenaert et al. 2026 (Gut Microbes, PMID: 42343233) — A major confirmation and extension: - Subjects with metabolic syndrome, daily pasteurized A. muciniphila MucT - Improved insulin sensitivity (Matsuda and HOMA-S indices) and GLP-1 excursion (p<0.05) - Reductions in body weight (p=0.06 trend) and decreased trunk fat (p<0.05) - Critical nuance: Benefits were conditional on low baseline Akkermansia levels — subjects with already adequate intestinal Akkermansia did not benefit. This is the "truly in need" principle.
Clinical Trial Landscape (2026 Meta-Synthesis)
Per a June 2026 meta-synthesis (NutricellScience), A. muciniphila has the richest human clinical evidence base of any next-generation probiotic: - Two RCTs in Nature Medicine (2019, 2026) - Effects replicated in overweight/obese, metabolic syndrome, and healthy medical worker cohorts - Consistent safety profile across trials - Ongoing trials registered on ClinicalTrials.gov (e.g., NCT05738746)
Practical Considerations
- Form: Pasteurized > live (based on all available RCT data)
- Amount used in trials: 10^10 cells/day
- Duration: Minimum 3 months to see metabolic effects
- Baseline testing: Stool testing for baseline Akkermansia levels may identify responders (low baseline = more likely to benefit)
- Regulatory: In the EU, pasteurized A. muciniphila was authorized as a novel food; in the US, it is sold as a dietary supplement (no FDA drug approval)
⚠️ Akkermansia is NOT a longevity result. No trial has tested A. muciniphila against any aging endpoint (lifespan, healthspan, epigenetic clocks). All human evidence is for metabolic parameters (insulin sensitivity, cholesterol, body composition). The longevity connection is associative (centenarian enrichment) and mechanistic (barrier integrity → reduced inflammaging), not demonstrated clinically.
05Short-Chain Fatty Acids (SCFAs): The Master Postbiotics
SCFAs — primarily butyrate, propionate, and acetate — are the main metabolic products of dietary fiber fermentation by gut bacteria. They function as signaling molecules, not just metabolic waste.
Butyrate
| Function | Mechanism |
|---|---|
| Colonocyte fuel | 70% of colonocyte energy comes from butyrate oxidation |
| Anti-inflammatory | Inhibits HDAC (histone deacetylase) → increases Foxp3+ Treg cells |
| Gut barrier | Upregulates tight junction proteins (claudin, occludin) |
| Metabolic | Activates GLP-1 and PYY secretion (satiety hormones) |
| Epigenetic | HDAC inhibition → tumor suppressor gene expression; potential anti-aging via epigenetic modulation |
| Mitochondrial | Improves mitochondrial function in peripheral tissues; increases beta-oxidation |
Swipe table →
Butyrate Producers: Faecalibacterium prausnitzii, Roseburia intestinalis, Eubacterium rectale, Anaerostipes hadrus
Propionate
- Hepatic gluconeogenesis signal; can reduce appetite via gut-brain axis
- Produced by Bacteroides, Akkermansia
- Linked to improved insulin sensitivity
Acetate
- Most abundant SCFA; substrate for butyrate production (cross-feeding)
- Reaches peripheral tissues; influences appetite and fat storage
- Produced by most fermenters
Dietary Fiber → SCFA Pipeline
The microbiome-SCFA axis explains much of the fiber-health association:
| Fiber Type | Microbial Conversion | Primary SCFA | Health Effect |
|---|---|---|---|
| Resistant starch | Ruminococcus bromii, Bifidobacterium | Butyrate | Colonocyte health, insulin sensitivity |
| Inulin/FOS | Bifidobacterium | Acetate → Butyrate (cross-feed) | Barrier integrity, immune |
| Beta-glucan (oats) | Multiple | Propionate | Cholesterol reduction, glycemic control |
| Pectin | Bacteroides | Acetate, propionate | Detoxification, bile acid metabolism |
| Polyphenols (flavonoids) | Akkermansia, Faecalibacterium | Multiple | Antioxidant, anti-inflammatory |
Swipe table →
Implication: The most reliable way to increase SCFA production is not supplementation (oral butyrate has poor bioavailability) but dietary fiber diversity — targeting 30+ different plant species per week (Tim Spector / Zoe model) to maximize microbial diversity and fermentation pathways.
06Postbiotics: The Next Frontier
Definition
Postbiotics are preparations of inanimate microorganisms and/or their components that confer a health benefit. Unlike probiotics (live bacteria), postbiotics contain defined microbial metabolites, cell wall components, or heat-killed bacteria that deliver clinical effects without requiring colonization.
Why Postbiotics?
- Safety — No risk of infection from live organisms (critical for immunocompromised)
- Stability — No cold chain required; defined shelf life
- Reproducibility — Standardized composition vs. variable probiotic viability
- Mechanism — Can deliver specific bioactive molecules (SCFAs, proteins, exopolysaccharides)
Key Postbiotic Preparations
| Postbiotic | Source | Evidence |
|---|---|---|
| Pasteurized Akkermansia | Heat-killed A. muciniphila | RCT-validated (see above) |
| Amuc_1100 protein | Recombinant A. muciniphila outer membrane protein | Animal + early human data |
| Sodium butyrate | Direct SCFA supplement | RCTs for IBS, IBD; mixed for metabolic |
| Heat-killed Lactobacillus | Various Lactobacillus spp. | Immune modulation; some RCTs |
| Exopolysaccharides | Lactobacillus, Bifidobacterium | Preclinical immune modulation |
Swipe table →
07Fecal Microbiota Transplantation (FMT) and Aging
Animal Evidence
- Smith et al. (2017) — FMT from young to old mice extended lifespan and improved cognitive function
- Boehm et al. (2020) — Co-housing young and old mice transferred youthful microbiome traits
- Multiple studies show FMT from young donors reverses age-related inflammation, cognitive decline, and intestinal barrier dysfunction in mice
Human Evidence (Emerging)
- No published human trials of FMT for longevity endpoints
- FMT is FDA-approved for recurrent C. difficile infection (not for aging)
- Exploratory trials for metabolic syndrome, IBS, and neurological conditions are ongoing
- Ethical and safety concerns remain significant for non-disease applications
08Gut-Brain Axis
The gut microbiome influences brain function through multiple pathways:
- Vagus nerve — Direct neural signaling from gut to brain
- SCFA absorption — Butyrate and propionate cross the BBB; influence neuroinflammation, microglial activation
- Neurotransmitter production — Gut bacteria produce GABA, serotonin, dopamine, acetylcholine precursors
- Immune signaling — Cytokines and immune cells traffic from gut to brain
- HPA axis — Microbiome influences cortisol and stress response
Clinical Relevance
- Depression/anxiety — Multiple RCTs show probiotic supplementation modestly improves mood scores (especially multi-strain formulations)
- Cognitive decline — Associations between microbiome dysbiosis and Alzheimer's, Parkinson's (see Stealth Pathogens for P. gingivalis and gut-brain connections)
- Autism — Early-life microbiome disruptions associated with ASD; FMT trials show preliminary benefit
09Practical Context
Tier 1: Foundational (Evidence: Strong)
| Intervention | Target |
|---|---|
| Diverse plant intake | Overall microbial diversity |
| Fermented foods | Lactobacillus, Bifidobacterium |
| Prebiotic fibers | SCFA production |
| Polyphenol-rich foods | Akkermansia, Faecalibacterium |
| Limit ultra-processed foods | Barrier integrity |
Swipe table →
Tier 2: Targeted (Evidence: Moderate)
| Intervention | Notes |
|---|---|
| Pasteurized Akkermansia | 10^10/day if low baseline; metabolic focus |
| Butyrate supplement (sodium butyrate) | — |
| Targeted probiotics | Lactobacillus rhamnosus GG, Bifidobacterium longum for specific conditions |
| Intermittent fasting | — |
Swipe table →
Tier 3: Experimental (Evidence: Emerging)
| Intervention | Notes |
|---|---|
| Stool testing (Zoe, Viome, GI Map) | Snapshot only; limited clinical utility without practitioner guidance |
| FMT | Only for recurrent C. difficile outside clinical trials |
| Postbiotic formulations | Emerging category; limited human RCTs outside Akkermansia |
Swipe table →
What Doesn't Work (or Is Overhyped)
- Multi-strain probiotic "shotgun" — Generic probiotics with 10+ strains show minimal benefit in healthy people; colonization is transient
- Collagen → microbiome — No evidence collagen peptides modulate microbiome composition
- "Detox" protocols — See Mold Illness, Mycotoxins, and CIRS for context on dubious binders/cleanses
10Microbiome Optimization
Core thesis: The gut microbiome — trillions of microorganisms residing in the GI tract — functions as a "second brain" and metabolic organ. Its composition profoundly influences immunity, mental health, metabolism, and disease risk. However, the field's complexity means most specific interventions are still being validated.
Key Facts
- 30-40 trillion microorganisms in the human gut — roughly 1:1 ratio with human cells
- 3.3 million genes in the gut microbiome vs. ~22,000 human genes
- Weight: ~1-2 kg of bacteria — the weight of a small organ
- Composition: ~1,000+ species, dominated by Bacteroidetes and Firmicutes phyla
- Uniqueness: Your microbiome is as individual as your fingerprint
Core Functions
- Digestion & nutrient absorption — ferment fiber to short-chain fatty acids (SCFAs)
- Immune regulation — 70-80% of immune tissue is gut-associated
- Barrier function — maintain tight junctions, prevent "leaky gut"
- Neurotransmitter production — ~95% of serotonin is produced in the gut
- Metabolism — influence energy extraction, fat storage, glucose regulation
- Detoxification — metabolize xenobiotics, hormones, bile acids
- Protection against pathogens — competitive exclusion
Diversity Is Key
- Higher microbial diversity consistently correlates with better health outcomes
- Western populations have significantly reduced diversity vs. traditional/hunter-gatherer populations
- Hadza hunter-gatherers have ~40% more species diversity than Westerners
- Each plant type feeds different microbial species → "eat the rainbow" has mechanistic basis
The Fermentation Continuum
| Substrate | Product | Effect |
|---|---|---|
| Dietary fiber | SCFAs (butyrate, propionate, acetate) | Anti-inflammatory, gut barrier repair, appetite regulation |
| Polyphenols | Bioactive metabolites | Antioxidant, anti-inflammatory |
| Resistant starch | Butyrate | Preferred fuel for colonocytes |
| Protein (excess) | Branched-chain fatty acids, ammonia, H2S | Potentially harmful in excess |
| Bile acids | Secondary bile acids | Signaling molecules, some carcinogenic |
Swipe table →
Short-Chain Fatty Acids (SCFAs)
Butyrate is the most important: - Primary energy source for colonocytes (colon cells) - Strengthens gut barrier via tight junction protein expression - Anti-inflammatory via HDAC inhibition - Regulates Treg cells (immune tolerance) - Improves insulin sensitivity - Produced by: Faecalibacterium prausnitzii, Roseburia intestinalis, Eubacterium rectale
Patterns of Dysbiosis
- Loss of diversity — reduced species richness
- Loss of keystone species — F. prausnitzii, Akkermansia muciniphila, Bifidobacterium
- Overgrowth of pathobionts — opportunistic species that cause problems when dominant
- Loss of SCFA production — butyrate producers decline
- Increased intestinal permeability — "leaky gut" → systemic inflammation
Drivers of Dysbiosis
| Factor | Mechanism |
|---|---|
| Antibiotics | Nuclear option — can devastate microbiome for 6-12 months+ |
| Ultra-processed food | Lacks fermentable substrate; emulsifiers damage barrier |
| Industrial seed oils | Alter membrane fatty acid composition |
| Chronic stress | HPA axis → gut motility/permeability changes |
| Sleep disruption | Circadian rhythm governs microbial oscillations |
| Artificial sweeteners | May induce glucose intolerance via microbiome |
| C-section birth / no breastfeeding | Reduced initial colonization diversity |
| NSAIDs / PPIs | Alter gastric pH, barrier function |
Swipe table →
1. Dietary Approaches (Strongest Evidence)
- Diverse plant intake: Aim for 30+ different plant foods per week (American Gut Project finding)
- Prebiotic fibers: Inulin, FOS, GOS, resistant starch, pectin — feed beneficial bacteria
- Fermented foods: Sauerkraut, kimchi, kefir, kombucha, miso — introduce live organisms
- Polyphenol-rich foods: Berries, dark chocolate, green tea, coffee, olive oil
- Minimize UPF: Ultra-processed foods lack fiber and contain microbiome-damaging additives
2. Prebiotic Supplementation
| Prebiotic | Source | Primary Effect |
|---|---|---|
| Inulin | Chicory root, Jerusalem artichoke | Bifidobacteria growth |
| Resistant starch | Green bananas, cooled potatoes | Butyrate production |
| FOS/GOS | Garlic, onion, legumes | Broad-spectrum fermentation |
| Psyllium | Seed husk | Bulking + fermentation |
| PHGG | Guar gum (partially hydrolyzed) | Gentle, well-tolerated prebiotic |
Swipe table →
3. Probiotic Strategy
- Lactobacillus/Bifidobacterium blends: General gut health support
- Saccharomyces boulardii: Prevent/treat antibiotic-associated diarrhea
- Akkermansia muciniphila: Emerging — strengthens gut barrier (PMID 28414284)
- Spore-based probiotics (Bacillus species): Claimed to survive gastric passage better
Critical caveat: Probiotic supplementation is imprecise. A 2018 study (PMID 30995525) found standard probiotics actually delayed microbiome recolonization after antibiotics, while FMT and self-FMT (autologous) restored it rapidly. One size does not fit all.
4. Fecal Microbiota Transplant (FMT)
- Strongest evidence: Recurrent C. difficile infection (>90% cure rate vs. ~30% for antibiotics)
- Emerging: IBS, IBD, metabolic syndrome, autism spectrum — results variable
- DIY FMT: Practiced in some communities but carries significant infection risk
- Meta-analysis on obesity: No significant improvement in metabolic parameters (PMC11404604)
- Key limitation: Standardization is difficult; donor selection is critical
5. Postbiotics
- Definition: Bioactive compounds produced by microbial fermentation
- Examples: Butyrate supplements, propionate, EPS (exopolysaccharides)
- Advantage: Bypass need for live organisms to colonize
- Evidence: Early but promising for gut barrier support
Testing the Microbiome
| Test | What It Shows | Utility |
|---|---|---|
| 16S rRNA sequencing | Relative abundance of bacterial taxa | Broad overview, limited resolution |
| Shotgun metagenomics | Species/strain level, functional genes | More comprehensive, more expensive |
| Organic acids test (OAT) | Metabolic byproducts | Indirect microbiome assessment |
| GI-MAP / GI Effects | Pathogens, commensals, markers | Clinical-grade stool testing |
| Zonulin + LPS | Gut permeability markers | Assess barrier function |
Swipe table →
11Connections
12Sources
- Tseng CH. From dysbiosis to longevity: a narrative review into the gut microbiome's impact on aging. Gut Microbes . 2025. PMC: PMC12515389PMC12515389
- Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers. Nat Med . 2019;25(7):1096–1103. PMID: 31263284 . doi 10.1038/s41591-019-0495-2PubMed 31263284 · DOI 10.1038/s41591-019-0495-2
- Suenaert P, et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome. Gut Microbes . 2026. PMID: 42343233 . doi 10.1080/19490976.2026.2690689PubMed 42343233 · DOI 10.1080/19490976.2026.2690689
- NCT05738746NCT05738746
- Ira R, et al. Understanding Aging through the Lens of Gut Microbiome. Explor Res Hypothesis Med . 2024;9(4):294–307. doi 10.14218/ERHM.2024.00008DOI 10.14218/ERHM.2024.00008
- Van Hul M, Cani PD. From microbiome to metabolism: bridging a two-decade translational gap. Cell Metab . 2026;38(1):14–32. doi 10.1016/j.cmet.2025.10.011DOI 10.1016/j.cmet.2025.10.011
- PubMed 28414284PubMed 28414284
- PubMed 30995525PubMed 30995525
- PMC11404604PMC11404604
13Entry history
Latest content update.
Folded in 1 earlier page: microbiome-optimization.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.